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Bisimidazoline arylamides binding to the DNA
minor groove: N1-hydroxylation enhances binding
affinity and selectivity to AATT sites†
Carlos H. Ríos Martínez,ab Laura Lagartera,a Cristina Trujilloc and
Christophe Dardonville*a
Bisimidazoline arylamides and related compounds are high affinity DNA minor groove binders with a pref-
erence for AT over GC-rich DNA. However, further selectivity towards different classes of AT-sites (e.g.,
CGAATTCG, CATATATAT) is not always observed with these series. In this work, we wanted to understand
the effect of imidazoline ring N-substitution on binding to DNA AT-sites. The structure–affinity relationships
of a series of structurally related bisimidazoline compounds were studied by UV titrations and surface
plasmon resonance (SPR) experiments using fish sperm DNA and different hairpin oligonucleotides. We
found that in this series, the presence of N1–OH groups enhances the binding affinity to dsDNA
CGAATTCG oligonucleotide, resulting in a higher selectivity for dsDNA containing AATT over (AT)4
sequences. The docking models showed that the N-hydroxy derivatives bind in a more planar conforma-
tion to the CGAATTCG DNA sequence, display more favorable van der Waals interactions, and show addi-
tional H-bonds with the bases and the sugar-phosphate backbone.
Introduction
Research efforts in the past few decades have led to a growing
understanding of the DNA structure and drug–DNA interac-
tions. Specific binding to DNA is thought to be achieved
either by the formation of hydrogen bonds between the ligand
and the base pairs of DNA or the recognition of a specific
sequence-dependent shape of the DNA double helix.1 In AT-
rich DNA, ligand-induced narrowing of the minor groove and
changes in the bending of the DNA helix upon complex for-
mation contribute to the binding of minor groove agents.2–4
Narrow minor grooves, often associated with the presence of
A-tracts, strongly enhance the electrostatic potential of the
DNA.5 These sequence-specific properties of DNA are used by
many DNA-binding proteins1 and minor-groove-targeting
compounds as a recognition mechanism. Hence, most of the
minor-groove ligands share some structural characteristics
(i.e., positive charge(s), linked rather than fused aromatic or
heteroaromatic rings, crescent shape –“isohelicity”– matching
the curve of the groove) that allow the ideal match between
the ligand and the groove through van der Waals and hydro-
gen bonding (HB) interactions.6
Minor groove binders are especially interesting DNA-
interacting compounds for antimicrobial drug design
because they are sequence selective (in contrast to inter-
calators which are sequence neutral), principally binding to
A/T-rich DNA duplexes. This selectivity is particularly relevant
in the case of parasitic pathogens such as trypanosomes
whose mitochondrial genome contains a high proportion of
A/T-rich DNA sequences.7 Due to their unique structural fea-
tures,8 the A/T-rich minicircles of mitochondrial kinetoplast
DNA (kDNA) appear to be the target for drug interaction.3,4,7
In previous studies, we have discovered diphenyl
dicationic compounds 1–5 (Chart 1) that showed excellent
in vivo activity against African trypanosomes (T. b.
rhodesiense) in mouse models of sleeping sickness.9–12 The
binding interaction of 5 with the minor groove of the all-AT
DNA sequence dĲAAAATTTT)2 and with the self-
complimentary nucleotide dĲCTTAATTCGAATTAAG)2 was
demonstrated by X-ray crystallography.13,14 Nagle et al.
showed that arylamide derivatives 1 and 2 bound strongly
and selectively to AT oligonucleotides with a slight preference
(2- to 3-fold) for dsDNA CGAATTCG vs. CATATATAT
sequences.15 The same group observed that N-substitution of
the guanidinium groups by hydroxyl radicals abolished
almost completely the binding affinity of these ligands.16
Similarly, reduction in DNA binding affinity was observed
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with diamidine and bisguanidine analogues whose cationic
moieties were derivatized with N-alkyl groups.10,17–19
The goal of the present study was to understand the effect
of imidazoline ring N-substitution on arylamide binding to
the minor groove of AT-rich DNA. As the here presented
results together with many other studies of minor groove
binders point to the involvement of shape-recognition by
DNA, it was important to determine the selectivity of binding
to different DNA sequences (i.e., DNA shapes). Hence, the
binding of a series of ten closely related guanidine and
imidazoline compounds (Chart 1) to unspecific fish-sperm
DNA and dsDNA containing CGAATTCG, CATATATAT, and
CGCGCGCG was studied by UV spectrophotometry and sur-
face plasmon resonance (SPR)-biosensor experiments. Molec-
ular docking studies using representative crystal structures of
both dsDNA oligonucleotides CGAATTCG (pdb: 1ENN) and
CATATATAT (pdb: 3TED) were carried out to rationalize the
findings.
Results and discussion
Spectrophotometric titrations
Compounds 1a and 1b have a strong absorption band at 280
nm, compounds 4a and 4c have a strong absorption band at
<250 nm and a weak absorption in the 300–360 nm region,
and 5a has a strong absorption band at 296 nm. These
absorption spectra were strongly perturbed when the
bisimidazolines formed a complex with unspecific fish-sperm
(FS) DNA (Fig. 1). Compounds 1a and 1b as well as 4a and 4c
exhibited isoabsorptive behaviours. For all of the compounds,
a clear isosbestic point was observed during titration, indicat-
ing a single dominant mode of binding to FS DNA. A weak
hypochromicity (9–34%) at the compound peak wavelength
was observed upon binding, which is consistent with minor
groove binding.
The binding of 1a to the specific dsDNA CGAATTCG hair-
pin oligonucleotide produced strong alterations in the UV
spectra (i.e. similar to that observed with FS DNA), whereas
the binding to dsDNA CATATATAT and CGCGCGCG
sequences induced much weaker changes (Fig. S1†). These
results suggested that 1a binds more specifically to the
dsDNA containing AATT. The absorption spectra were
strongly perturbed when 5a formed a complex with dsDNA
containing AATT (Fig. S1†). An isosbestic point at 325 nm
indicated a single mode of interaction with the AATT hairpin.
A new band attributed to the compound–DNA complex
appeared at approximately 335 nm. Upon interaction with
the (AT)4 hairpin, an isosbestic point at 335 nm was observed
and a weak band attributed to the compound–DNA complex
appeared at 340 nm. In contrast, no isosbestic point or new
band was observed during titration with the (CG)4 sequence.
This is consistent with the absence of strong interaction of
5a with CG-rich DNA.
SPR-biosensor experiments
The DNA binding affinity and stoichiometry of the com-
pounds were determined using SPR-biosensor experiments
with the three DNA hairpin duplexes [i.e., AATT, (AT)4, (CG)4]
immobilized on a biosensor chip surface.20,21 The SPR
response (RU) at equilibrium in the SPR sensorgrams (i.e., in
the plateau region) was converted to r (moles of bound com-
pound per mole of DNA hairpin duplex; r = RU/RUmax) and
plotted against the free compound concentration, Cf, flowing
on the chip surface (i.e., immobilized DNA hairpin) (Fig. 2).
The binding constants were determined by fitting the values
to single-site or two-site binding models according to eqn (1)
Fig. 1 UV titration of 1a, 1b, 4a, 4c, and 5a (30 μM) with FS DNA in 10
mM phosphate buffer (pH 7) at 25 °C. FS-DNA concentrations ranged
from 0 to 7.89 × 10−5 M (1a), 0 to 1.8 × 10−4 M (1b), 0 to 2.89 × 10−4 M
(4a), 0 to 1.37 × 10−4 M (4c), and 0 to 1.16 × 10−4 M (5a) from top to
bottom.
Chart 1 Structures of the bisimidazoline arylamides (1, 1a, and 1b) and
analogues (2–5) used in this study.
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(see the experimental part). When two binding sites exist for
a given DNA sequence, only the primary binding constant is
given.
Structure–affinity relationships
SPR experiments showed that none of the compounds bind
significantly to the dsDNA containing (CG)4 sequences as
expected for this class of minor groove binders. The
bisimidazoline arylamide derivatives (1, 1a, and 1b) were the
strongest DNA binders. However, different binding behaviors
and affinities were observed depending on the spacer linking
both the phenyl groups and the N1-substituent on the
imidazoline rings (Table 1). The main SAR results are
presented below.
Effect of linker modification: ethylene, urea and amino
analogues
Bisimidazolines (1, 1a, and 1b) and bisguanidine (2, 2d, and
2e) arylamide derivatives showed the highest binding affini-
ties for AT oligonucleotides with a slight preference for
dsDNA containing AATT over (AT)4 sequences (1.5 to 2-fold).
The binding of all of the compounds except for 3d to AT
sequences was adjusted to a two-site binding model. The
primary binding constants were about 100 times higher
than the secondary binding constants. Compounds with
a urea linker (3, 3d) displayed only weak affinity for DNA
(KD > 8.06 × 10
−6 M) with no sequence selectivity for
AT-oligonucleotides and moderate selectivity towards CG for
3 (~10- to 50-fold). These results together with the ratio of
moles of bound compound per mole of DNA hairpin duplex
(r ≥ 2 for most sequences) are consistent with an intercala-
tion mode of binding and/or external electrostatic interac-
tions for the urea-derived compounds 3 and 3d.
Fig. 2 SPR binding affinity. (1) Sensorgrams for binding of 1a to
CGAATTCG and CATATATAT hairpin duplexes using increasing
concentrations of the ligand in the range 0.05–57.6 μM (from bottom
to top). (2) SPR binding plots of 1a for AATT, (AT)4 and CGCGCGCG
hairpins.
Table 1 DNA binding constants determined by SPR for dsDNA containing AATT, (AT)4, and (CG)4 sequences
a
Structure Cmpd R
dsDNA CGAATTCG dsDNA CATATATAT dsDNA CGCGCGCG
KD (×10
−6M)b KD (×10
−6M)b KD (×10
−6 M)
1 H 0.166c 0.307c >10d,e
1a OH 0.077 0.273 18.5
1b OMe 0.256 0.351 >10d
2 H 0.141 f 0.556 f >10d
2d Et 1.23g 1.92g >10e
2e iPr 1.02g 2.5g >10e
3 H 11.6 8.06 400–158.7
3d Et >29 >29 d
4 H 2.78 4.35 19.6
4a OH 0.870 4.0 76.9
4c OEt >29 >29e >29
5 H 2.70 2.17h d
5a OH 0.568 1.79 66.7
a dsDNA hairpins used in the study (the loop is underlined): 5′-biotin-CGAATTCGT_C_T_C_CGAATTCG-3′ [short name: AATT], 5′-biotin-
CATATATATC_C_C_C_ATATATATG-3′ [short name: (AT)4], and 5′-biotin-CGCGCGCGT_T_T_T_CGCGCGCG-3′ [short name: (CG)4].
b Primary binding
constant for fitting to a two-site binding model. c Nagle et al.15 reported similar binding constants for AATT and (AT)4 oligonucleotides (0.107 ×
10−6 M and 0.210 × 10−6 M, respectively). d There is not enough signal-to-noise ratio to get a binding constant for this hairpin oligonucleotide.
e Non-specific binding. f Taken from ref. 15. g Taken from ref. 10. h Taken from ref. 14.
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The binding affinities of the ethylene linked compounds
(4, 4a, and 4c) were 10- to 15-fold weaker than those of the
arylamide analogues (1a–b–2d–e), but 2- to 4-times stronger
than those of the urea analogues (3, 3d). The primary binding
of 4 and 4a to AT sequences was 5 to 10-fold and 30 to 50-
fold stronger than the secondary binding, respectively. The
amino-linked compounds 5 and 5a bind to dsDNA containing
AATT more weakly than the arylamide analogues 1 and 1a
(15- and 7-fold, respectively).
All together, these results clearly demonstrate the strong
influence of the linker on the DNA binding mode and affin-
ity, and that the arylamide scaffold (“amide linker”) is a
privileged scaffold for AT-site DNA binding, independent of
the cationic moieties present in the molecule.15
Effect of “imidazoline↔ guanidine” group modification
Guanidines bind somewhat less strongly than imidazoline
analogues. Substitution of the guanidine with alkyl groups
(2d, 2e) decreased the binding affinity for AT sequences (6 to
9-fold).10 These results agree with previous studies showing
that the bisimidazolines of this class bind more strongly and
selectively to AT-rich DNA than their guanidine counterparts,
probably due to more favorable van der Waals interactions of
the imidazoline rings with the minor groove.11,12,14 Crystallo-
graphic studies of 5 bound to dsAT-DNA have shown that
these favorable interactions also promote bifurcated hydro-
gen bonds between the imidazoline endocyclic nitrogens and
thymine and adenine atoms in opposite DNA strands that
facilitate the recognition of both strands of the DNA within
the minor groove.13,14
Effect of N1-substituents on AT-site selectivity
The most remarkable effect of the imidazoline N1 substitu-
ents was observed with hydroxyl groups. A two-fold increase
in affinity towards dsDNA containing AATT was observed for
1b in comparison with the unsubstituted parent compound 1
(KAATT = 0.077 × 10
−6 M and 0.166 × 10−6 M, respectively). In
contrast, no change in binding affinity to the dsDNA
CATATATAT sequence was observed. Thus, N1-hydroxylation
resulted in a 3.5-fold selectivity enhancement for dsDNA
containing AATT sequences over (AT)4.
The same results were observed for the ethylene-linked
N-hydroxy derivative 4a (KAATT = 0.87 × 10
−6 M vs. 2.78 × 10−6
M for the unsubstituted parent compound 4) and the amino-
linked compound 5a (KAATT = 0.568 × 10
−6 M vs. 2.70 × 10−6
M for the parent compound 5) showing that this effect may
possibly be generalised to other bisimidazolines. On the con-
trary, the introduction of alkoxy groups (OMe, OEt) was detri-
mental to the binding to AT-rich DNA, indicating that the OH
group of N-hydroxyimidazolines is probably involved in addi-
tional stabilization of H-bond interactions with the DNA
minor groove.
Noteworthy is the binding behaviour of the N-hydroxy
derivative 5a. The kinetics of binding to AT sequences
is rather different from the rest of the compounds with a
slow dissociation process (Fig. 3). Since the stoichiometry
(r value) is > 2, the results suggest a different, more com-
plex, binding mode to AT sequences. We recently made
similar observations with a 39 bp dsDNA containing
GAATAATCGCGATTATTC which formed a slow-binding (kon =
38 M−1 s−1) long-lasting (koff = 0.00265 s
−1) complex with 5a
(Dr. L. Campos, personal communication). This result is
important as longer drug–target residence time is considered
a key driving force for the pharmacodynamic activity and effi-
cacy of many drugs in vivo.22–25
Molecular docking studies
In order to understand the reasons behind the increased
affinity of the N-hydroxy derivatives, docking experiments
were run using the crystal structures of dĲGCGAATTCG)
[1ENN]26 and dĲCCATATATATGC) [3TED]27 as templates for
the dsDNA containing AATT and (AT)4 sequences, respec-
tively. The docking experiments were able to rank correctly
(i.e. in agreement with the experimental values) the ligands
into two groups of high (1a > 5a > 1 ≈ 5 ≈ 4a > 4) and low
(3 > 4c > 3d) predicted binding affinity, respectively (Table
S1†). However, the differences in binding affinities were too
small (i.e. within the limits of the standard error of the calcu-
lation) and did not allow us to extract useful conclusions in
relation to the increased affinity of the N-hydroxy derivatives
for the dsDNA containing AATT. Hence, a detailed study of
Fig. 3 (1) Sensorgrams for binding of 4a and 5a to CGAATTCG and
CATATATAT hairpin duplexes using increasing concentrations of the
ligand in the range 0.05–57.6 μM (from bottom to top). For 5a, the
shape of the sensorgram clearly shows a different profile with a slow
binding and dissociation process. (2) SPR binding plots of 4a and 5a for
AATT and (AT)4 hairpins.
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the interactions of lead 1 and its N-hydroxy analogue 1a with
both AATT and (AT)4 sequences was carried out.
In contrast to the dsDNA containing CATATATAT where
the ligands bind in a more twisted conformation, the phenyl
rings of 1 and 1a adopt a more coplanar conformation when
bound to the dsDNA CGAATTCG (Fig. S3–S6†). These results
agree well with the induced-fit observed with this kind of
ligand when bound to a narrow minor groove.14 An analysis
of the non-covalent interactions28 in the ligand–DNA com-
plexes showed that 1 and 1a form more (and larger) weak
attractive interactions with the dsDNA containing CGAATTCG
compared to that containing CATATATAT (Fig. S7†), which is
consistent with the values of binding affinities measured
experimentally.
Finally, the analysis of the HB interactions in the com-
plexes of 1 and 1a with CGAATTCG and CATATATAT oligonu-
cleotides showed distinctive patterns depending on the pres-
ence or absence of the N–OH group (Fig. 4 and S8†). For
instance, 1 forms two HBs (2.19 and 2.50 Å) with the phos-
phate groups of the sugar-phosphate backbone and 1 HB
(2.35 Å) with the O4′ atom of the A5 deoxyribose of the
dsDNA GCGAATTCG (Fig. S8_A†).
In contrast, 1a forms a strong HB between the OH group
and the O4′ atom of the C17 deoxyribose (Fig. 4, 1.98 Å) and
three HBs (2.03, 2.82, and 2.86 Å) with the phosphate groups
of the sugar-phosphate backbone (i.e. with the amide NH
and the imidazoline NH from both sides of the molecule,
respectively). With the dĲCCATATATATGC) oligonucleotide, 1a
forms 1 HB (2.30 Å) with the O4′ atom of the A9 deoxyribose
and a bifurcated HB between thymine T6 and imidazoline
N(2)H (2.25 Å) and N(1)OH (2.19 Å) (Fig. 4) which is absent
in the complex with compound 1 (Fig. S8_C†).
As a whole, the docking studies indicate that the better fit
of the N-hydroxy derivatives in the narrow minor groove of
the dsDNA containing AATT may be due to favorable van der
Waals interactions with the walls of the groove, a more pla-
nar conformation of the bound ligand, and additional stabi-
lizing H-bonds between the N–OH groups and sugar residues
and/or the base edges.
Conclusions
We have shown that N-substituted diphenyl-based bisimidazoline
compounds bind strongly to dsDNA, preferentially to A/T
containing oligonucleotides. The presence of one hydroxyl
substituent on each imidazoline endocyclic nitrogen (N1–OH)
results in an increase in binding affinity for the dsDNA
containing AATT sequences and no change in affinity for the
dsDNA containing (AT)4. This is translated into an increase
in sequence selectivity for the dsDNA CGAATTCG (3.5-fold).
This effect, which seems to be general for this family of
imidazoline compounds (e.g., 1a, 4a, and 5a), differs from
that observed with N-hydroxy guanidine analogues which
were found to bind poorly to DNA.16 Since the dsDNA
sequence CGAATTCG has a very narrow minor groove of
3.5–4.0 Å in the center of the sequence (vs. 5.16–6.79 Å for
ATAT) and a concomitant higher electrostatic potential,5 the
selective binding of the N-hydroxy bisimidazolines seems to
be derived from a tighter fit to this narrower groove.
Remarkably, in the case of 5a, the introduction of OH sub-
stituents increases the affinity for dsDNA CGAATTCG but also
results in a different stoichiometry (i.e. drug/DNA, 2 : 1 vs. 1 :
1 for 5) and an increased residence time on the DNA. Because
the longer half-life of the drug–target complex will minimize
the binding to off-target proteins, this kinetic selectivity may
improve the therapeutic index of 5a.23,24 Hence, further stud-
ies on this compound are warranted.29
Experimental
Syntheses of compounds 1,11 1a,9 1b,9 2,11 2d,10 2e,10 3,11
3d,9 4,30 4a,9 4c,9 5,31 and 5a32 have been described
previously.
UV titrations
The UV-vis spectra were measured on a Perkin-Elmer Lambda
35 UV–vis spectrophotometer in a 1.5 mL quartz cuvette
(1 cm pathlength) in 10 mM phosphate buffer (pH 7) previ-
ously degassed by sonication. A stock solution of FS-DNA in 5
mL of phosphate buffer was prepared and shaken gently for
1 h. The concentration of the FS-DNA stock solution (C = 780
Fig. 4 Plot of hydrogen bond (HB) interactions for 1a docked with
dĲGCGAATTCG) (top) and dĲCCATATATATGC) (bottom)
oligonucleotides.
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μM) was worked out from the following equation: Abs260 =
100 × C × d × ε260 using an extinction coefficient of 12 800
MĲbp)−1 cm−1 at 260 nm for FS-DNA.33
The DNA oligonucleotides 5′-CGAATTCGTCTCCGAATTCG-
3′, 5′-CATATATATCCCCATATATATG-3′ and 5′-CGCGCGCGTT-
TTCGCGCGCG-3′ were purchased from Eurofins MWG
Operon with HPLC purification. They were stored at −20 °C
as 100 μM stock solutions in phosphate buffer (pH 7)
containing 1 mM EDTA + 100 mM NaCl until use. Before
titration experiments, the oligonucleotides were diluted 10×
with phosphate buffer (pH 7) + 100 mM NaCl, heated at
90 °C in a water bath for 10 minutes, and immediately
chilled with ice to favour hairpin formation.
Stock solutions of compounds 1a, 1b, 4a, 4c, and 5a (C =
30 μM and C = 2.5 μM in phosphate buffer) were prepared
from 1 mM stock solutions in DMSO by dilution with 10 mM
phosphate buffer. The final amount of DMSO in the stock
solution was 3%. Spectrophotometric titrations were
performed by sequential addition of aliquots of the FS DNA
solution (C = 780 μM) to 800 μL of the compound (C = 30
μM) or hairpin oligonucleotide (C = 10 μM) to 500 μL of the
compound (C = 2.5 μM) until saturation was observed. The
experiments were performed at 25 °C. The spectra were nor-
malized and plotted using GraphPad (Prism).
SPR studies
SPR experiments were performed at 25 °C with a Biacore X-100
apparatus (GE Healthcare, Biacore AB, Uppsala, Sweden) in a
MES buffer (10 mM 2-(N-morpholino)ethanesulfonic acid, 1
mM EDTA, 100 mM NaCl, 0.005% surfactant P20, pH 6.25). The
5′-biotin labeled DNA hairpins 5′-CGAATTCGTCTCCGAATTCG-3′,
5′-CATATATATCCCCATATATATG-3′, and 5′-CGCGCGCGTTTT-
CGCGCGCG-3′ were purchased from Sigma-Aldrich with HPLC
purification, dissolved in the experimental buffer and used as
such. SPR measurements were carried out as described.10
The number of binding sites and the binding constants at
equilibrium were obtained from fitting plots of r (r = RU/
RUmax) against Cf. The maximum expected response (RUmax)
per bound compound at equilibrium was calculated using a
refractive index value of 1.4 as reported for similar com-
pounds.34 The results of the binding constants were obtained
by fitting the SPR results to a one-site (K2 = 0) or a two-site
binding model according to eqn (1):
r = (K1Cf + 2K1K2Cf
2)/(1 + K1Cf + K1K2Cf
2) (1)
where r is the number of moles of bound compound per
mole of DNA hairpin duplex, K1 and K2 are the microscopic
binding constants, and Cf is the free compound concentra-
tion at equilibrium.20,35
Computational details
All compounds have been optimized using the Gaussian0936
package at the B3LYP37,38 computational level with the
6-311++GĲd,p)39 basis sets. The effect of water solvation was
then accounted using the SCFR-PCM approach implemented
in the Gaussian09 package including the dispersion, repulsion
and cavitation energy terms of the solvent in the optimization.
A molecular docking study was undertaken using the
AutoDock Vina 1.1.2 modelling software.40 The compounds
were docked into representative crystal structures of dsDNA
containing CGAATTCG [i.e. dĲGCGAATTCG)2: pdb 1ENN]
26
and CATATATAT [i.e., CCATATATATGC, pdb 3TED].27 The
structures were imported into the AutoDock Vina 1.1.2
modelling software and all crystallographic water molecules
and other small molecules were removed as they were located
away from the ligand-binding regions. AutoDockTools 1.5.6
was used for establishing the Autogrid points as well as for
visualization of docked ligand–nucleic acid structures. The
target site on the nucleic acid was specified to encompass the
entire minor groove site. The grid center was also established
by centering the grid box on the minor groove site. The Non-
Covalent Interaction (NCI) index, based on the reduced gradi-
ent of the electron density, has been calculated to identify
attractive and repulsive interactions using the program NCI28
and plotted using the program VMD.41
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